Sir,
Acinetobacter baumannii isolates are resistant to many drugs and can cause severe infections with high mortality rates. 1 The emergence of A. baumannii isolates with carbapenem resistance is a matter of great concern. In the October 2012 issue, Huang et al 2 conducted a retrospective study to identify the risk factors and outcomes of patients with carbapenem-resistant A. baumannii (CRAB) bacteremia, as compared to carbapenem-susceptible A. baumannii bacteremia. This study demonstrated three independent factors of 14-day mortality due to CRAB, i.e., a high Acute Physiology and Chronic Health Evaluation (APACHE) score, the presence of shock, and inappropriate antimicrobial therapy. From Huang's results, two of these risk factors were related to disease severity of bacteremia and were not remediable at the time of diseases onset. However, early appropriate antimicrobial therapy may be able to improve the clinical outcome.
Conversely, inappropriate empirical antimicrobial therapy (IEAT) is a potentially modifiable factor, which has been associated with increased mortality in patients presented with a critical illness. 3 However, the optimal approach for empirical antibiotic therapy in critical patients with A. baumannii bacteremia remains controversial. A retrospective cohort study was conducted in a university hospital. The data from 130 patients with bacteremia caused by A. baumannii, who presented with critical illness (defined as a Pitt bacteremia score 4 points) was analyzed. Among this cohort, 27 (20.8%) patients acquired CRAB bacteremia, 94 (72.3%) individuals acquired multidrug-resistant bacteremia, and 51 (39.2%) patients received IEAT. The 30-day crude mortality rate was statistically higher among patients receiving IEAT than that of those initially treated by appropriate (in vitro active) antibiotic regimens (32/63, 50.8% vs. 21/67, 31.3%; p Z 0.032). Moreover, empirical combination regimens directed against A. baumannii (i.e., a carbapenem plus sulbactam or an aminoglycoside) were less likely to be inappropriate than monotherapy (8/33, 24.2% vs. 44/97, 45.4%; p Z 0.003). A survival analysis of Cox regression model was applied, after adjusting for age, gender, and underlying disease (McCabe classification), and found that patients with empirical combination therapy had a lower mortality rate (adjusted odds ratio Z 0.31; 95% confidence interval: 0.15e0.72; p Z 0.006) (Fig. 1) . Expected benefits of empirical combination therapy for bacteremia caused by resistant organisms, are based on the following rationale: to broaden coverage providing at least one appropriate activity, 4 or to exploit the synergy activity. 5 Our study suggests that the use of empirical combination antimicrobial therapy will be associated with more appropriateness for patients with critical illness due to A. baumannii bacteremia and with a favorable outcome. Therefore, it appears reasonable to initiate empirical combination antimicrobial therapy directed against A. baumannii bacteremia in critically ill patients. This recommendation may be seriously considered for critical patients at risk of A. baumannii infections, or in the clinical settings of the presence of endemic multidrug-resistant A. baumannii in healthcare facilities. However, the optimal empirical combination regimens directed against A. baumannii infections, should be based on local antimicrobial susceptibility patterns.
